KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Analytical Chemistry / 2020 / Cilt: 2 - Sayı: 1

Voltammetric analysis of class II antiarrhythmic drugs propranolol and acebutolol

Dilek KUL
Fatma AĞIN
Sayfa
47–54
Yayın Tarihi
2020-06-23
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Finally, voltammetric behavior of the drugs in real samples such as human serum and urine was evaluated and it was examined whether the analysis results were affected by the other substances in real samples.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Antiarrhythmic agents are used to suppress abnormal rhythms of the heart.
📊
Temel Bulgular & Veri:Scan rate results obtained with the voltammetric methods showed whether the redox process of the drug active ingredient diffusion or adsorption controlled on the electrode used in the selected supporting electrolyte.
💡
Sonuç & Katkı:Finally, voltammetric behavior of the drugs in real samples such as human serum and urine was evaluated and it was examined whether the analysis results were affected by the other substances in real samples.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Beta blockers · Acebutolol · Propranolol

Abstract

Antiarrhythmic agents are used to suppress abnormal rhythms of the heart. Class II antiarrhythmic agents are beta blockers used to treat supraventricular tachycardias. Voltammetric analysis of class II antiarrhythmic drug active ingredients propranolol and acebutolol carried out with various modified/non-modified electrodes using cyclic voltammetry, linear sweep voltammetry, differential pulse voltammetry and square wave voltammetry were compiled from the literature. The effect of buffer solution and pH was investigated. Scan rate results obtained with the voltammetric methods showed whether the redox process of the drug active ingredient diffusion or adsorption controlled on the electrode used in the selected supporting electrolyte. Results of the quantitative analysis of these drugs were evaluated in terms of parameters such as linearity range, limit of detection, stability, robustness, repeatability, reproducibility and sensitivity. Accuracy and precision of the validated methods were investigated by combining the results obtained from the pharmaceutical dosage forms of the drug active ingredients. Finally, voltammetric behavior of the drugs in real samples such as human serum and urine was evaluated and it was examined whether the analysis results were affected by the other substances in real samples.

🔖

Bu Makaleye Atıf Yap

KUL, D., AĞIN, F. (2020). Voltammetric analysis of class II antiarrhythmic drugs propranolol and acebutolol. Turkish Journal of Analytical Chemistry, Cilt: 2 - Sayı: 1, 47–54. https://ajindex.com/articles/808295

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. J.E. Bager, P. Hjerpe, K. Manhem, S. Bjorck, S. Franzen, A. Rosengren, S.A. Eryd, Treatment of hypertension in old patients without previous cardiovascular disease, J Hypertens, 37, 2019, 2269-2279.
  2. P.K. Whelton, N.R.C. Campbell, D.T. Lackland, G. Parati, C.V.S. Ram, M.A. Weber, X.H. Zhang, Strategies for prevention of cardiovascular disease in adults with hypertension, J Clin Hypertens, 22, 2020, 132-134.
  3. J. Naish, D.S. Court, Medical Sciences, second ed., Saunders Ltd., London, 2014, p. 562. N.R. Poulter, D. Prabhakaran, M. Caulfield, Hypertension, Lancet, 386, 2015, 801–12.
  4. R. McManus, M. Constanti, C.N. Floyd, M. Glover, A.S. Wierzbicki, Managing cardiovascular disease risk in hypertension, Lancet, 395, 2020, 869-870.
  5. V.P. Arcangelo, A.M. Peterson, Pharmacotherapeutics for Advanced Practice: A Practical Approach, fourth ed., Lippincott Williams & Wilkins, Philadelphia, 2016, p. 205. T.I. Chang, M.J. Sarnak, Intensive blood pressure targets and kidney disease, Clin J Am Soc Nephrol, 13, 2018, 1575-1577.
  6. A. Duni, E. Dounousi, P. Pavlakou, T. Eleftheriadis, V. Liakopoulos, Hypertension in chronic kidney disease: Novel insights, Curr Hypertens Rev, 16, 2020, 45-54.
  7. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright, E.J. Roccella, Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, Hypertension, 42, 2003, 1206–1252.
  8. A.S. Go, M.A. Bauman, S.M. Coleman King, G.C. Fonarow, W. Lawrence, K.A. Williams, E. Sanchez, An effective approach to high blood pressure control: A science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention, Hypertension, 63, 2014, 878–85.
  9. C.S. Wiysonge, H.A. Bradley, J. Volmink, B.M. Mayosi, L.H. Opie, Beta-blockers for hypertension, Cochrane Database Syst Rev, 1, 2017, CD002003.
  10. S.W. Chan, M. Hu, B. Tomlinson, The pharmacogenetics of beta-adrenergic receptor antagonists in the treatment of hypertension and heart failure, Expert Opin Drug Metab Toxicol, 8, 2012, 767-790.
  11. Y. Agrawal, J.K. Kalavakunta., V. Gupta, Antiarrhythmic agent induced ventricular tachycardia, Am J Ther, 24, 2017, E487-E487. E.M. Vaughan Williams, A classification of antiarrhythmic actions reassessed after a decade of new drugs, J Clin Pharmacol, 24, 1984, 129-147.
  12. P. Brugada, The Vaughan-Williams classification of antiarrhythmic drugs - Why do